Meeting notes - good meeting
attendees 15-20 including from Boston and Indiana.
Best dressed: the guy rocking the baseball cap and denim shirt.
Bearded guy, Indiana, Boston and Baseball Cap all asked several questions. Dr. M answered all questions.
Insights:
-4 years cash is the policy - as we know Dr. M has been great at raising cash with minimal dilution.
-future trials can select for genomics that respond best to 273 - wild type is 80%. he noted that biogen and Lilly rejected 80% of the potential trial participants and still only an inconclusive result on effectiveness, So 273 can claim to much wider market.
-Current alz drugs approveed with biomarkers, so we will go same route.
-5 years of OZ data now, although number at around 20-24 is not significant
Timing:
-Mostly vague "this year" Bearded guy pressed on this but didn't get much.
- 6 month long PD trial to start "soon"
- US will be before seeking Oz approval, reason is better pricing.
- They have 30mg and 50mg data for alz but will only release as part of complete data release "this year" (my take is this is in part to leave shorts with no target, drop the MOAB with zero warning, hehe)
- Partners - they have credible contract manufacturer which is needed for approval, so that base covered. Final decision on marketing partner after approval for max $$$.
- Multiple Schlerosis - they approached MS foundation after Wayne State studies came out, MS wanted more proof to get funding. but they will go back to them and MS still on the agenda. My read of the tea leaves is after an approval for alz or rett.
- sounded like full data for alz will be before Rett results.
-question on whether or not there was brain regrowth - no data on that, (my take, perhaps the PD imaging trial will show that)
Pricing: perhaps the best part of meeting
As there are other prices out there now for Rett and Alz, they provide guideposts.
Rett, the competitor price is $500K per year. figure on some percentage of that.
Alz competitor is $26K per year. So I am sticking with my $12-24K guess.
cannot convert alz pill into a liquid form. so separate pricing.
Ample interest from alz partners.
-
-
